How scientific publication strategy serves as a biotech marketing engine

Key takeaways

• A planned publication strategy turns trial data into credibility with clinicians, payers and investors instead of a box checked after each study.
• Journal choice, PubMed indexing, open access and timing decide who actually sees your evidence.
• Long-term KOL relationships, congress presentations and preprints extend the reach of each dataset.
• HEOR, real-world evidence and guideline citations support market access and investor confidence.
• Follow GPP 2022 and ICMJE authorship rules, and keep promotional use within FDA’s 2025 SIUU guidance.

Scientific publication strategy works as a biotech marketing engine because peer-reviewed evidence is what clinicians, payers and investors trust most. Many biotech companies treat publishing as a task to finish after each trial. The companies gaining ground plan publications from the start, so each dataset reaches the right audience at the right time. This Emulent guide explains how to build that plan responsibly.

What benefits does a strategic approach to scientific publishing offer biotech companies?

A strategic approach links what you publish, where and when to the audiences who need the evidence. Publishing without a plan can leave strong data in journals your target clinicians never read, or released after the moment it would have mattered most.

Planning early is an ethical standard as well as a marketing tactic. The Good Publication Practice guidelines for company-sponsored research, GPP 2022, published in Annals of Internal Medicine, call for publication plans, steering committees and transparent authorship. A plan made near trial start shows that results were published as intended rather than selected after the fact.

• Peer-reviewed publications show physicians and medical affairs teams that efficacy and safety data have passed independent review.
• Payers and health technology assessment groups review published health economics and outcomes research (HEOR) when making coverage decisions.
• Regular publication in respected journals shows institutional investors that your science is credible and your pipeline is advancing.
• Publications that match registered trial results build a consistent public record alongside ClinicalTrials.gov reporting.

How do peer-reviewed journals build credibility with stakeholders?

Peer-reviewed journals build credibility because they are how the medical community validates new therapies. Journal choice decides who sees your work. A Phase II trial in a general oncology journal reaches a different audience than the same data in a subspecialty journal read by the physicians who would prescribe your therapy.

• Check the journal’s readership and editorial focus to confirm your target clinicians read and contribute to it.
• Confirm PubMed and MEDLINE indexing, since that is where physicians and researchers search.
• Consider open access, which removes paywalls for clinicians, payers and partners without institutional subscriptions.
• Factor in review time, since some journals take six months or more and launches and regulatory milestones have fixed dates.

How does collaborating with KOLs (leading physicians and researchers) strengthen your publication strategy?

Collaborating with KOLs strengthens your strategy because senior physicians and researchers carry influence with clinicians and payers alike. Good KOL engagement is a years-long scientific relationship, not a one-time request before a conference.

• Involve KOLs early in study design and endpoint selection, which creates real scientific investment beyond authorship.
• Give advisory boards meaningful input on research direction rather than using them as a formality.
• Support investigator-initiated studies, which produce publications with a level of independence company studies cannot match.
• Help KOLs submit abstracts to major congresses such as ASCO, ASH and AACR.

Every author must meet ICMJE authorship criteria, medical writing support must be disclosed and payments to physicians must be reported under Open Payments.

How do conference presentations expand your data’s impact?

Conference presentations expand impact by putting data in front of practicing physicians, often before the full paper appears. Abstracts are frequently published online ahead of peer-reviewed articles, so strong congress data builds anticipation for the publication.

Preprints on bioRxiv and medRxiv have also become part of the process, letting results circulate before peer review. They suit some audiences, such as investors and fellow researchers, but should be clearly labeled as not yet peer reviewed.

• Posters at specialty congresses let your team and KOLs discuss data directly with treating physicians.
• Late-breaking abstract slots draw outsized media and peer attention for significant findings.
• Industry-sponsored satellite symposia offer deeper education on disease context and mechanism, within promotional rules.
• Published presentations, video summaries and press coverage extend the life of data beyond the event.

How does a publication strategy support investor relationships and market access?

A publication strategy supports investors and market access because both groups read peer-reviewed data when judging a therapy. Institutional investors, venture firms and biotech analysts follow publications as part of due diligence, and payers expect published evidence by the time contract talks begin.

• HEOR studies in journals such as PharmacoEconomics and Value in Health reach the decision-makers who set formulary placement.
• Real-world evidence from registries or health record datasets shows how a therapy performs outside trials.
• Inclusion in third-party systematic reviews and meta-analyses provides outside validation.
• Publications that inform clinical practice guidelines, such as those from the National Comprehensive Cancer Network, shape treatment and coverage.

When commercial teams share publications with healthcare providers, follow FDA rules. FDA’s January 2025 final guidance on communicating scientific information on unapproved uses sets out how firms can share reprints and clinical reference resources about unapproved uses truthfully and separately from promotion.

How do you build a publication plan that serves both science and marketing?

You build a plan that serves both by matching evidence to the audiences who need it while protecting scientific integrity. A useful plan is a living document maintained from Phase I onward.

• A data asset inventory listing every study, sub-analysis and real-world dataset, with the clinical story each supports.
• Audience-based journal mapping that ranks target journals by the audience each reaches.
• KOL authorship assignments with timelines that allow real scientific contribution.
• A congress abstract calendar tied to data readouts.
• A regular gap analysis comparing your published evidence with competitors’.

Publish negative and neutral results as well as positive ones. Selective publication damages trust with clinicians and reviewers far more than an unfavorable result.

How do you put your publication strategy to work?

You put the strategy to work by treating each publication as a long-lived asset. A well-placed, peer-reviewed article can be cited for years in guidelines, payer dossiers and investor materials, so its value grows over time.

Emulent helps biotech companies connect publication strategy with websites, content and digital campaigns that carry published evidence to clinicians, payers and investors, within medical, legal and regulatory review. If you want a publication strategy that supports clinical adoption, payer access and investor confidence, contact the Emulent team.